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Abstract: Porous inorganic nanostructured materials are widely used nowadays as drug delivery 
carriers due to their adventurous features: suitable architecture, large surface area and stability in 
the biological fluids. Among the different types of inorganic porous materials, silica, calcium 
carbonate, and calcium phosphate have received significant attention in the last decade. The use of 
porous inorganic materials as drug carriers for cancer therapy, gene delivery etc. has the potential 
to improve the life expectancy of the patients affected by the disease. The main goal of this review 
is to provide general information on the current state of the art of synthesis of the inorganic porous 
particles based on silica, calcium carbonate and calcium phosphate. Special focus is dedicated to the 
loading capacity, controllable release of drugs under internal biological stimuli (e.g., pH, redox, 
enzymes) and external noninvasive stimuli (e.g., light, magnetic field, and ultrasound). Moreover, 
the diverse compounds to deliver with silica, calcium carbonate and calcium phosphate particles, 
ranging from the commercial drugs to genetic materials are also discussed. 
Keywords: drug delivery systems; silica-based particles; calcium carbonate; calcium phosphate; in 
vitro and in vivo delivery; drug loading 
 
1. Introduction 
Nanoscale materials attract a significant interest in the industrial and research communities. 
These smart functional materials, which are made up of diverse components, offer tremendous 
opportunities in the field of biomedical applications, especially, in cancer therapy [1,2]. The 
development of porous materials for the cancer research is mainly determined by the unique ability 
to control physico-chemical characteristics and properties of these materials [3,4]. At the same time, 
controllable properties allow to design multifunctional materials, enabling bioimaging, sensing, as 
well as their therapeutic applications [5]. The porous nano-/microparticles are considered to be the 
most appropriate carriers for the drug delivery. Among them, silica, calcium carbonate and calcium 
phosphate are promising vehicles [6–8]. These particles are able to transport the huge loads of 
anticancer or therapeutic bioactive molecules to the desired sites for the disease treatments, owning 
higher efficiency and lower side effects compared to the individual drugs [9]. The drug carriers based 
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on silica, calcium carbonate and calcium phosphate nano-/microparticles possess several advantages 
such as improved pharmacokinetic profile, possibility to employ lipophilic drugs, higher circulation 
time in comparison to the administration of the free drugs and lower overall toxicity due to the lower 
dosages used [10]. A broad range of the pore sizes (2–50 nm) of porous carriers allows loading of 
therapeutic agents of different nature, such as low-molecular weight drugs, proteins, genetic 
materials (plasmid deoxyribonucleic acids (DNA), ribonucleic acids (RNA)). The available surface 
area and pore networks provide possibility to incorporate even inorganic nanoparticles (for example, 
iron oxide, gold, silver nanoparticles, quantum dots, etc.) [11–13]. The inclusion of the inorganic 
nanoparticles into the porous structure of the carriers leads to the formation of hybrid materials. 
These materials combine the properties of both components of the hybrid system (porous carriers 
and inorganic nanoparticles) [10]. The progress in this field includes the fabrication of porous micro- 
and nanocarriers modified with, for example, magnetic nanoparticles, what enables the sensitivity of 
the carriers to the external magnetic field [14]. Combination of various properties in one intelligent 
carrier provides their multifunctionality for the potential use in the medical diagnostic and cancer 
therapy. These include in vivo tracking of drug vehicles using magnetic resonance imaging (MRI), 
application of various field-dependent magnetic behaviors to reach greater concentrations of 
functionalized drug-particulate systems in the desired areas in vivo. The multifunctional properties 
can be also achieved when incorporating gold nanoparticles or quantum dots into the porous 
structure. As known, the coupling of the strong near-infrared plasmon resonance absorption of gold 
nanoparticles into the thermal energy is an example of a nanoscale phenomenon that has been widely 
exploited to photothermally destroy malignant tumors. As a result, the gold-functionalized porous 
carriers are able to deliver antitumor drugs into cancer cells and simultaneously deliberate 
photothermal properties [15,16]. In addition, the impregnation of inorganic nanoparticles that are 
intrinsically responsive to different kinds of stimuli allows to form multi-stimuli responsive drug 
carriers [17]. Employing different types of stimuli (internal or external), a rapid or prolonged release 
profile can be achieved suggesting multiple drug regimens to improve clinical success [18,19]. 
Particularly, the multi-functionalized carriers combining two or more stimuli-responsive 
mechanisms hold greater potential for controlling drug release process and improving therapeutic 
performance [20]. The surface of porous carriers can be easily functionalized by a variety of ligands 
such as antibodies, aptamers, bioactive polymers, and peptides for higher in vivo stability in the 
blood stream (e.g., using PEGylation to avoid macrophage capture, and/or adjusting active targeting 
properties for the carriers accumulation in the desired area) [21]. Moreover, the size of porous carriers 
can be tuned using different synthetic approaches. Varying the size and shape of the particles, it is 
possible to control the internalization process in different cell types [22,23]. In addition, silica, calcium 
carbonate and calcium phosphate-based carriers are biodegradable and can be safely excreted by the 
body through the kidney. Figure 1 schematically represents the main advantages of the employment 
of the porous carriers in the drug delivery applications. 
Scope 
Hundreds of review papers devoted to the use of particles as drug delivery carriers have been 
published in recent years. The majority of review articles dedicated to these materials are focused 
either on one type of porous particles (e.g., silica, calcium carbonate or calcium phosphate), or on the 
very general description of porous materials [10,24]. The present review paper aims to provide an 
overview of three promising types of porous inorganic carriers (silica, calcium carbonate and calcium 
phosphate). It aims to summarize recent progress in research on the use of porous silica, calcium 
carbonate and calcium phosphate carriers for the delivery of drugs in vitro and in vivo. This review 
is not meant to be an exhaustive description of details of either of these technologies or to summarize 
all existing research on it, but to give a perspective onto these three existing approaches, their 
advantages, limitations and current state of research progress so that the reader can get a lay of land 
and plan research accordingly. For each type of carriers there are many comprehensive review papers 
that can provide an in-depth look into them in general or into a particular aspect of those, be it 
synthesis, drug loading, drug release or biomedical applications. For the porous materials synthesis 
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(especially, silica), the readers can be also referred to the excellent review articles [25,26]. 
Additionally, detailed description of the different functionalization strategies for the decoration of 
nanomaterials with various compounds can be found [27]. 
This review consists of three sections, not including introduction and conclusions. Each section 
describes one of the considered porous material (silica, calcium carbonate or calcium phosphate) and 
is organized as follows: synthesis methods of the porous carriers, drug loading approaches, cargo 
release, and in vitro/in vivo drug delivery applications. 
 
Figure 1. Schematic overview of some advantages of porous carriers for the drug delivery 
applications. 
2. Silica-Based Drug Carriers 
The porous silica-based carriers can be divided into three types: mesoporous silica nanoparticles 
(MSNs), mesoporous organosilica nanoparticles (MONs) and periodic mesoporous organosilica 
(PMO). MSNs category is the most used particulate system [27]. Other two types of silica-based 
carriers (MONs and PMO) are emerging as new generation of silica hybrid analogs. The advantages 
of silica-based carriers include well-studied, predictable and low-cost manufacturing process. They 
are chemically stable what allows them to protect fragile cargo (such as DNA) from the 
biodegradation before they reach their intended destination. Moreover, silica-based particles are 
biodegradable at the long term and can be cleared from the organism after several days [1]. In the 
previous study, it has been demonstrated that the clearance rate of MSNs is primarily dependent on 
the particle shape. Short-rod shaped silica nanoparticles showed faster clearance rate compared with 
the long-rod shaped MSNs [28]. Another study indicated hepatobiliary clearance of silica 
nanoparticles observed over a period of 15 days in vivo [29]. The surface properties of MSNs play 
also significant role in in vivo excretion. He et al. showed that differently coated silica particles (OH–
SiNPs, COOH–SiNPs, and polyethylene glycol (PEG)–SiNPs) were cleared from the systemic blood 
circulation, but the clearance time and subsequent biological organ deposition were dependent on 
the surface chemical modification of the MSNs [30]. 
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2.1. Preparation Methods and Physical Chemistry of Silica-Based Carriers 
MSNs, MONs, and PMO are commonly fabricated using sol-gel processes in aqueous solutions 
[9,31–33]. The conventional sol-gel synthesis has been studied extensively and allow precise control 
of MSNs properties: size, pore size and geometry, particle modification or surface functionalization 
[31]. In the typical sol-gel synthesis, silica particles are formed via hydrolysis of various silanes and/or 
silicates with a subsequent silica condensation: 
–Si–O– + HO–Si– → –Si–O–Si– + OH–  
Synthesis process takes place in an aqueous solution and may involve alcohol and ammonia or 
other catalyst [32]. The synthesis reaction speed depends on the pH value with the maximum silica 
condensation rate at normal pH conditions. Types and concentrations of the used reagents affect the 
resulting particle size. Tetraethyl orthosilicate (TEOS), tetramethyl orthosilicate (TMOS) and other 
compounds can be used as silicon sources. Using TMOS facilitates the generation of monodispersed 
particles since it reacts preferentially with the silanol groups on the surface of already formed 
particles rather than with itself to create the new particles [33]. To inhibit silica growth and, thus, 
obtain smaller MSNs, surface-protection agents can be used, such as triethanolamine (TEA), poly 
(ethylene glycol) (PEG) or a second nonionic surfactant [34]. These agents are also useful for the 
isolation of the growing silica particles from each other, preventing their aggregation and growth of 
silica bridges between neighboring particles. 
To obtain MSNs, micelles are often used as a soft template to form the mesoporous structure. 
The silica particles are grown on the templates as starting points for the condensation. Surfactants 
such as cetyltrimethylammonium bromide (CTAB) are usually added to the solution as well. At low 
concentrations just above the critical micellar concentration, the surfactant molecules bind together 
and form small spherical micelles. At higher concentrations, micelles can have cylindrical or other 
shapes. These micelles are positively charged and attract negatively charged silanes, facilitating their 
condensation. Addition of the second surfactant can lead to the formation of the more complicated 
micellar structures, allowing further modification of the MSNs pore structure. Similar to the micelles, 
vesicles can be used as templates for the MSN growth [35]. Inorganic nanoparticles, such as metal 
(Au, Pt) or metal oxide (Fe3O4) nanoparticles could be incorporated into the structure of MSNs [36–
38]. They can be used as the templates for the MSNs growth as well. So synthesized hybrid particles 
can be capable of both carrying a drug load and being contrast agents for bioimaging, for example. 
Some applications require larger pore sizes to accommodate higher quantities of molecules or 
simply larger biomolecules, such as DNA and proteins. Several swelling agents can be used to 
increase the pore sizes, e.g., trimethylbenzene (TMB) [39]. Another way to increase the size of the 
pores is the use of the block-polymers as templates [40]. 
After the growth, the templates need to be removed from the MSNs in a way that does not 
damage the particles. Due to the high thermal stability of silica, simple calcination process can 
eliminate the most organic templates from the MSNs. However, drying causes MSNs to get into close 
contact with each other and develop bonds by the dehydration of the surface silanol groups, thus 
damaging them. Therefore, simple calcination is not the preferable method of template removal. A 
so-called “liquid calcination” method has been developed using high boiling solvents to retain liquid 
phase during calcination. Silanol groups can also be removed from MSN surface via a silane ethanol 
solution, reducing the bridging. The calcination process could be avoided entirely if templating is 
done using a thermosensitive polymer (poly (N-isopropylacrylamide)), which forms aggregates at 
higher temperatures and dissolves at lower temperatures [41]. 
The mixture of silane [usually tetraethyl orthosilicate(TEOS)] and an organosilane induces the 
formation of MONs and PMO. In this case, the surfactant templates should be removed with less 
aggressive extraction procedures, in order not to destroy the inorganic-organic framework of MONs 
and PMO. The calcination procedure, which is usually used for MSNs, is not completely appropriate 
for MONs and PMO. In general, harsh pH and temperature conditions are usually employed for the 
extracting process. The silica-etching chemistry [alkaline or hydrofluoric acid(HF) etching] is 
introduced into the synthesis to form the hollow PMO structure [42]. For this, the PMO layer is 
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directly deposited onto the surface of silica particles in order to form well-defined solid silica 
core/PMO shell. The chemical stability of some families of PMOs is higher than for the silica particles 
under etching. Therefore, the silica core can be selectively removed under alkaline or HF etching 
producing hollow periodic mesoporous structure. For instance, Wu et al. have successfully 
developed the strategy for the fabrication of hollow-structured mesoporous silica particles with the 
large pore sizes and the organic-inorganic hybrid frameworks [2]. Another example of the fabrication 
of hollow periodic MONs was demonstrated by Chen et al. [43]. 
The high attention on silica-based carriers can be associated with their versatility in size, 
morphology, and texture. The uniform silica particles of different diameters can be prepared using 
various synthetic conditions (e.g., controlling pH values or time of reaction) (Figure 2A,B). For 
instance, Fang Lu et al. [44] developed a simple method for tailoring the size of well-ordered and 
dispersed MSNs by adjusting the pH of the reaction medium, which leads to the series of MSNs with 
diameter sizes ranging from 30 to 280 nm (Figure 2A). It also possible to control particle growth at 
different times of the reaction (Figure 2B). Smaller particles (140 nm) emerged for 160 s into the 
reaction process grew to their final size (500 nm) in 600 s. Optimizing the particle size is highly 
important for the biomedical applications, since the size, shape and morphology of particles can 
significantly influence cell uptake, accumulation inside tissues and organelles. 
Since the efficiency of drug loading and its further release depends on the pore structure and 
composition, it is very important to control the pore parameters for the developing of drug carriers 
with the optimal pore sizes. Sol-gel chemistry is the most suitable method to obtain highly ordered 
silica-based materials with different pore sizes. By varying conditions of sol-gel synthesis through 
templating and pore-swelling agents, different porous silica-based materials can be prepared, which 
define the structural diversity of the silica-based carriers. The small-pore MSNs with radially 
disposed disordered pores (about 3 nm) are shown in Figure 2C. These materials can be prepared 
using a procedure where the common base NaOH was replaced by the polyalcohol triethanolamine 
(TEA). Thus, this allows conducting the synthesis at a lower pH values, while the condensation is 
influenced by the chelating properties of the TEA. By combining these features with the specific time- 
and temperature-profiles, discrete mesoporous nanoparticles with narrow particle size distributions 
can be prepared [34]. The synthesis of MSNs with ordered pores of about 4 nm with a helical 
arrangement and an amino-functionalized MSNs with expanded stellate pores of about 5 nm can be 
synthesized in the basic reaction solutions [45]. It is also possible to fabricate the MSNs with the 
bottleneck pores of about 10 nm (large pore MSN or LP-MSN) and single pore MSNs with even larger 
pore diameters (15 nm) using an adapted acidic synthesis strategy, which was described in the Ref. 
[46]. Thus, there are many possibilities available for tuning structure and functionality of MSNs by 
means of synthetic strategies. At the same time, the composition of the mesoporous walls can be 
modified with organic moieties, which allow manipulating the loading efficiency of drugs, as well as 
their release behavior upon internal and external triggering stimuli [45]. 
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Figure 2. TEM images of silica-based carriers with tunable diameters and pore size. (A–E) Reproduced 
with permission from [31]. Royal Society of Chemistry, 2013; (F–J) Reproduced with permission from 
[33]. American Chemical Society, 2007; (K–O) Reproduced with permission from [45]. American 
Chemical Society, 2017. 
2.2. Drug Loading Approaches 
There are different approaches to load the cargo into the silica-based carriers. The incorporation 
of drugs into the pores of silica-based materials is widely reported. MSNs can be loaded with 
hydrophobic and hydrophilic drugs. The hydrophobic drugs can be loaded via noncovalent pore-
drug interactions, such as electrostatic bonding between negatively charge silica pores and positively 
charge functional groups of drugs (e.g., doxorubicin, vincristine). The main disadvantage of this drug 
loading approach is that open pores leave the drug free to interact with the surroundings, allowing 
leakage and degradation. To overcome this problem, several loading strategies have been developed. 
The loading of diverse therapeutic small-sized compounds can be performed using the outer surface 
engineered approach, when the surface of MSNs are functionalized with polymers, proteins, lipids, 
or nanoparticles. The polymer coating block the diffusion of the loaded drugs [3,4,47,48]. Moreover, 
the grafting of nanoparticles (a few nanometers in diameter) onto silica surface allows incorporating 
drugs. As an example, Lin and colleagues reported the use of the gold nanospheres [49], iron oxide 
nanospheres [50] etc. The loading of drugs could be achieved by change of the protein conformation 
or electrostatic interactions between protein and drug [48,51]. Besides outer surface engineered 
approach, the pores of silica can be functionalized with organic groups of organosilane to enhance 
the drug loading efficiency [4,51]. The organic functional groups of MONs can interact with active 
drugs via electrostatic forces, chemical bonding, or noncovalent interactions. For instance, Lin and 
co-workers developed MSNs with amino-coumarin functional groups, which can covalently link to 
the anticancer drug chlorambucil [52]. The uniquely hybridized structure and composition of PMO 
carriers allows enhancing the loading capacity [49]. The hybridized pore walls of PMO carriers 
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provide strong noncovalent pore-drug interactions and possess a tunable 
hydrophobicity/hydrophilicity. As a result, many drugs can be loaded in exceptionally high contests 
into PMO carriers without leakage even in the absence of pore capping agents [53]. 
2.3. Release Efficiency 
The mechanism of drug loading is closely connected with its release, thus the desired conditions 
of cargo release determine the coating method. Two distinct mechanisms of payload release can be 
distinguished: triggering from internal factors, in this case the release occurs when MSN environment 
reaches certain predetermined conditions, and triggering from external factors, when an outside 
influence is required for the release to occur (Figure 3). With an internal triggering, release conditions 
can be chosen close to the conditions inside or near cancerous cells, for example, to deliver 
chemotherapeutic drugs such as doxorubicin to their targets. With an external triggering, it is possible 
to select the area for the drug release by applying, for example, light or magnetic field locally. 
2.3.1. Internal Triggering 
pH trigger: The pH values of surrounding environment can trigger the release of cargo from 
silica-based carriers. Warburg effect states that pH value is reduced near cancerous cells due to their 
energy metabolism. The pH value drops even further in endo/lysosomal environment. This can be 
used to deliver bioactive compounds with further release in acidic conditions inside cells. The loaded 
cargo can be protected from the leakage in acidic environment by capping the MSN pores with pH-
labile bonds, such as acetal or amine bonds, boronate or hydrazine groups. These bonds can hold the 
cargo inside the pores in a neutral or alkaline environment; however, they will be hydrolyzed in an 
acidic environment, releasing the cargo. For example, several groups have demonstrated pH-
responsive release of doxorubicin from MSNs covered by poly (acrylic acid), poly (styrene sulfonate) 
or other polyelectrolyte multilayers [51,52,54]. Coating MSNs with a cell-penetrating peptide (deca-
lysine sequence K10) and capping them with ZnO nanoparticles was shown to have “zero-
premature” drug release in the physiological environment and rapid release inside cancerous cells’ 
endosomes [55]. Other possibilities of pH-triggered release mechanisms have been tried, including 
pH-degradable calcium phosphate coating [56] and poly (L-histidine) coating [57]. 
Redox trigger: Redox triggering is based on the difference in glutathione (GSH) concentration 
inside intracellular and extracellular environment. The ability of GSH to reduce disulfide bonds is 
often used for triggering cargo release. GSH concentration inside cells is several orders of magnitude 
higher, which allows the cargo to be very well-contained before it is internalized by a cell and released 
afterwards [58]. Moreover, the GSH concentration is considerably higher in cancerous cells due to 
their higher metabolic rate in comparison with normal cells. Thus, linking the cargo to the MSNs via 
disulfide bonds will lead to the release of the cargo in the intracellular environment. Alternatively, 
MSNs with loaded cargo can be capped by macromolecules linked via GSH-sensitive bonds. Various 
molecules have been studied for this, including β-cyclodextrin [59], peptides [60], hyaluronic acid 
[61], PEG and other polymers [62–64]. Besides capping the pores, these macromolecules can act as 
targeting agents for the MSNs or serve for other purposes, raising the efficiency of the drug delivery 
system as a whole. Moreover, disulfide bonds can be introduced directly into MSNs, so that GSH 
would cleave the MSNs themselves into smaller pieces after delivery, which would also increase their 
biodegradability and ensure better clearance [65,66]. 
Enzyme trigger: Enzymes play crucial role in the cell metabolism. Their activity is complicated 
and enzymes expression levels can vary a lot between different types of cancerous and normal cells. 
Careful choose of the capping molecule enables the MSN opening after the contact with the certain 
enzymes. Enzyme triggering can be very efficient, for this, the capping molecules should have bonds 
that can be degraded by enzymes which are overexpressed in the cancer cells [67]. Therefore, various 
studies have been performed where anticancer drugs were loaded into MSNs sensitive to the tumor 
enzymes [64]. 
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2.3.2. External Triggering 
Photochemical trigger. Light is a very convenient external trigger for several reasons. It can be 
easily localized in the treatment area, can be applied noninvasively, as well as delivered inside body 
cavities via waveguides, affecting only specific compounds tied to a specific wavelength [52]. It has 
been widely used for targeting tumors in, e.g., photodynamic therapy. There are several 
photosensitive groups that can be cleaved by light of specific wavelength. For example, o-nitrobenzyl 
ester group can be cleaved by 350 nm UV light. It was used to cap MSNs with cyclodextrine or other 
groups to be opened remotely [65,66]. Another example is coumarin that was used to seal a model 
dye inside MSNs with β-cyclodextrin using two-photon excitation [68]. Doxorubicin was loaded into 
MSNs capped with coumarin-based block copolymer that was degraded by two-photon infrared (IR) 
irradiation [69]. Two-photon processes are beneficial in biomedical applications because they allow 
more precise localized effects. Another photochemical reaction that can be used to trigger the cargo 
release from MSNs is photoisomerization, when the capping is not cleaved, but “opened” by 
changing its shape. For example, azobenzene can be switched between its cis and trans forms when 
exposed to ultraviolet (UV) and visible light, respectively. Azobenzene and β-cyclodextrin were used 
in creating valves to load or release the model drug doxorubicin inside the MSNs [70]. 
Thermal trigger. While cancerous tissues usually have slightly elevated temperatures, which can 
be used for internal triggering, external heating can result in considerably higher temperature 
variations. Heating can be done either directly or indirectly, by light or alternating (AC) magnetic 
field. When metal plasmonic nanoparticles embedded into MSNs are irradiated by light, efficient 
plasmonic heating may occur via light absorption. By using laser pulses of short duration (picosecond 
or femtosecond) MSNs can be heated to high temperatures while keeping the heating localized near 
the MSNs, since heat does not have enough time to spread around and damage surrounding area for 
the pulse duration. As an example, paraffin has been used to seal the cargo inside the MSN. After 
heating the MSN above the paraffin melting point, it opened and released the cargo [71]. Coiled-coil 
peptides were also used as MSN cappings [72]. They remain in coiled state while the temperature is 
below 80 °C, sealing the MSN pores; when the temperature rises above, the coiled-coils disassemble 
and open the pores. Several groups have used poly-N-isopropylacrylamide (PNIPAAm) as a 
thermoresponsive capping since it swells via absorbing water and shrinks via dehydration at elevated 
temperatures [69]. 
Magnetic trigger. Magnetic fields are used to open MSN pores indirectly. First, embedding 
magnetic nanoparticles inside the MSNs allows their heating by applying AC magnetic field. These 
MSNs can then be opened via thermal-triggered mechanism and cargo, e.g., doxorubicin [73], can be 
delivered. AC magnetic field could also induce a mechanical effect and “squeeze” the cargo out of 
MSN pores. A considerable advantage of magnetic fields is that they produce little to no harmful 
effect on the organism by themselves, even in comparison with light. Magnetic nanoparticles used in 
this approach can also be used as contrast agents in magnetic resonance image (MRI), helping with 
both visualizing and healing [71]. 
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Figure 3. Schematic presentation of a variety of external and internal triggering mechanisms for 
delivery of bioactive compounds using porous silica-based carriers  
2.4. Delivery of Various Compounds In Vitro and In Vivo  
The aforementioned methods of loading and controlled/modulated release of drugs have been 
used in many studies to deliver a variety of cargo, including model drugs and fluorescent dyes (Table 
1). For instance, Wang et al. [74] have developed a pH-triggered drug delivery system by layer-by-
layer assembly of chitosan (CHI)/dialdehyde starch (DAS) polyelectrolyte multilayers (PEM) onto 
MSNs. The formed carriers were used to deliver doxorubicin by changing pH values in vitro. In 
neutral environment the release of cargo was shown to be slow, whereas at pH 5 the breakage of C=N 
bonds of the CHI/DAS multilayers resulted in rapid release of doxorubicin. To improve the escape of 
delivered cargo from the endo/lysosomal compartments after endocytosis, Zhang et al. [61] coated 
MSNs with a kind of cell-penetrating peptide, deca-lysine sequence (K10). Additionally, ZnO 
quantum dots were used as capping agents, which are able to dissolve in acidic environment. 
Synthesized multifunctional carriers were employed in vitro and showed synergistic antitumor 
effect, as well as preventing premature drug release from MSNs. In vivo studies have been performed 
as well. For instance, Zhang et al. demonstrated improved uptake of functionalized with folate 
ligands silica nanoparticles into tumor, as well as delivery of doxorubicin and subsequent inhibition 
of the tumor growth in mice [75]. Chemotherapeutic drug doxorubicin was also co-delivered with 
antiangiogenic agent combretastatin A4 with porous silica particles in vivo in the work of Li [76]. The 
release of combretatatin A4 resulted in disruption of vascular structure, in addition to the 
chemotherapeutic effect of doxorubicin on tumor. 
Ze-Yong et al. also delivered doxorubicin using silica particles in vitro. Fabricated particles were 
glutathione (GSH) responsive, since the surface of the MSNs was modified with arginylglycylaspartic 
acid (RGD) peptide using disuldife bonds. As a result, almost no drug leakage from the carrier, as 
well as efficient receptor mediated endocytosis was observed [60]. The improved study of 
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biodegradability of GSH responsive MSNs loaded with doxorubicin was reported by Wang et al. [77] 
After analysis, it was demonstrated that after interaction with GSH, carriers were broken into small 
pieces. Moreover, the negligible hemolytic activity and low cytotoxicity show the excellent 
biocompatibility of studied particles in vitro. Zhang et al. conjugated hyaluronic acid (HA) with the 
surface of the MSNs. In this case, HA served not only as a GSH-responsive capping agent capping, 
but also as a targeting agent, significantly increasing cellular uptake in HeLa cells in comparison to 
human hepatocyte cells (LO2) cells. Doxorubicin hydrochloride was successfully delivered with the 
synthesized multifunctional carriers in vitro [61]. 
Previous studies demonstrated successful delivery of nucleic acid with porous silica 
nanoparticles. Wang and colleagues delivered messenger RNA (mRNA) loaded into the silica-based 
nanoparticles pores in vivo [78]. Delivery of nucleic acids and, thus, cell transfection, with silica 
carriers can be improved by functionalizing of nanoparticles with polyethyleneimine (PEI). However, 
this can significantly reduce safety profile of porous silica nanoparticles [79].  
As it has been mentioned, controllable properties, biocompatibility and biodegradability makes 
MSNs a great candidate for clinical applications. Silica as a material has been generally considered 
safe for a long time which should help MSNs get regulatory approval. Unfortunately, there have not 
been many clinical trials involving MSNs yet [80]. A couple of trials involving silica-gold nanoparticle 
have taken place [80]. They were used not to deliver drugs, but to induce plasmonic heating via IR 
irradiation [81]. There was, however, one successful clinical trial of so-called Cornell dots, which used 
silica hybrid nanoparticles to deliver cyanine (Cy5) dye and iodine (124I) to facilitate Positron Emission 
Tomography imaging [82]. The nanoparticles were also modified with cyclic arginine–glycine–
aspartic acid (cRGDY) peptides for molecular targeting. The success of the trial proves the potential 
of silica nanoparticles and paves the way for further clinical evaluation of various MSN-based drug 
delivery systems. 
However, some previous studies in vitro and in vivo showed toxicity and certain hazard effects 
using MSNs. These adverse effects of MSNs depended on the cell type and physico-chemical 
properties of MSNs (e.g., size, shape, chemical composition). For example, silica-based carriers may 
cause the generation of oxidative stress in cells via formation of reactive oxygen species (ROS) [83]. 
Moreover, it has been shown that it can contribute to the decreasing of glutathione level in cells [84], 
as well as in the induction of antioxidant enzymes [85]. All above mentioned effects can cause the cell 
membrane damage. Some works reported that the size of silica particles can play a crucial role in the 
particles toxicity. Cho et al. demonstrated that bigger silica particles (100 and 200 nm) induced 
inflammatory response of the liver in vivo, whereas smaller silica particles (50 nm) not [86]. Thus, 
before introduction silica particles in preclinical/clinical studies, it is important to investigate 
potential toxicity of these carriers on cells and tissue. 




Active Drug In Vitro/In Vivo Results Ref. 
Sol-gel method 
Mix CTAB with NaOH 
solution. Add TEOS at 80 °C 
to the surfactant solution. 
Calcination was performed at 
550 °C for 6 h. 
100 nm Doxorubicin 
The folate-receptor-mediated targeted delivery was 
proved by qualitative confocal laser scanning 
microscopy (CLSM) measurement. Cellular uptake of 
the doxorubicin-loaded nanoparticles in folate 
receptor-overexpressing HeLa cells was detected to 
be much higher than that in non-folate receptor-
overexpressing adenocarcinomic human alveolar 
basal epithelial cells (A549) cells. 
[74] 
Sol-gel method 
Mix CTAB with NaOH 
solution. Add TEOS at 80 °C 
to the surfactant solution. 
Collect precipitate, wash with 
water and methanol, dry with 
vacuum. Resuspend particles 
in methanol, HCl and stir at 
60 °C for 48 h.  
200 nm Doxorubicin 
The human liver cancer cell line (HepG2) cells 
viability with drug-loaded ZnO@MSN decreased 
below 50% at a concentration of 50 µg/mL, which is 
two times lower than that viability of cells incubated 
with free doxorubicin. 
[55] 





with sulfonic groups in 
ethanol and ammonia. Add 
TEOS and stir under 50 °C for 




200 nm Doxorubicin 
Synthesized GSH-responsive hollow silica 
nanoparticles showed near 3-fold higher doxorubicin 
release at pH 5.0 than at pH 7.4 without the presence 
of GSH. Qualitative CLSM observations confirmed 
that  doxorubicin-loaded nanocarriers were 
internalized and the drug was released to reach cell 
nuclei within 24 h. 
[77] 
Sol-gel method 
Mix CTAB with NaOH 
solution. Add TEOS at 80 °C 
to the surfactant solution. 
To remove CTAB, reflux in 
HCl and methanol for 16 h. 
150 nm  Doxorubicin 
Synthesized GSH responsive silica nanoparticles 
capped with peptide incubated separately with avβ3-
integrin-positive tumor cell line (U87 MG) and avβ3-
integrin-negative cell line (COS 7) at a doxorubicin 
concentration of 2 µg mL−1 possessed 1.7-fold higher 
U87 MG cellular uptake than that of silica 
nanoparticles without peptide. There was very little 
difference between the carriers in COS 7. 
[60] 
Sol-gel method 
Mix CTAB with NaOH 
solution. Add TEOS at 80 °C 
to the surfactant solution. 
To remove CTAB, add 
ethanol and HCl at 60 °C for 
24 h. 
40 nm Doxorubicin 
Hyaluronic acid modified silica-based nanocarriers 
showed redox-responsive drug release and high drug 
loading (14%). The developed carriers were 
internalized in 2-fold higher amounts in HeLa cells 
than in LO2 cells. 
[61] 
Sol-gel method 
Mix CTAB with NaOH 
solution. Add TEOS at 80 °C 
to the surfactant solution. 
Calcination was performed at 




GSH-responsive PEG-capped silica-based particles 
were used to deliver safranin O and doxorubicin in a 
controlled manner in vitro, achieving 90% of the 
maximum release of the entrapped drug in less than 1 
h. The results showed that the PEG-capped systems 
were closed at low GSH concentrations. The cargo 




Mix CTAB with NaOH 
solution. Add TEOS at 80 °C 
to the surfactant solution. 
Calcination was performed at 




Polymer-gatekeeper mesoporous silica nanoparticles 
were synthesized by noncovalent capping of the 
pores of drug-loaded nanocontainers with disulfide 
cross-linkable polymers. By varying crosslinking 
density from 19% to 83%, the drug release was 
decreased almost in 2-fold. 
[64] 
Template method 
Add TEOS to the polystyrene 
latex nanoparticles.  
Calcination was performed at 
600 °C to remove polystyrene 
nanoparticles. 
150 nm Doxorubicin 
The in vitro experiments indicated that the silica-
based nanocarriers modified by near infrared (NIR)-
light responsive polymers had a considerable drug 
loading efficiency of more than 70%. A significant 
number of drug molecules (>50%) could be released 
from the nanocarriers upon NIR-light irradiation. 
[69] 
Mix CTAB with NaOH 
solution. Add TEOS and 
APTES at 80 °C to the 
surfactant solution. 
Wash with ethanol. 
100 nm Doxorubicin 
A novel multifunctional envelope-type mesoporous 
silica nanoparticle system was used for drug delivery 
and magnetic resonance imaging (MRI) in vivo. The 
doxorubicin release was markedly increased under 
acidic conditions; more than 60% and 90% of the drug 
were released at pH 5.0 and pH 2.0, respectively. 
[87] 
Sol-gel method 
Mix CTAB with NaOH 
solution. Add TEOS at 80 °C 
to the surfactant solution. 
To remove CTAB, reflux in 





The cumulative drug release from the synthesized 
MSN@Fe3O4 nanocarriers was increased from 0.2% to 
about 21.9% over a 5 min magnetic stimulus. 
Obtained carriers showed T2-type MR contrast 
enhancement for cell or molecular imaging. 
[88] 
3. Calcium Carbonate Drug Carriers 
Apart from the porous silica-based carriers, porous calcium carbonate (CaCO3) has been studied 
as a potential candidate for the encapsulation of different drugs for decades [89–91]. CaCO3 naturally 
presents as calcite, aragonite and vaterite forms. The crystallization of CaCO3 polymorphs occurs 
through the formation and subsequent transformation of amorphous calcium carbonate (ACC) by 
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following pathway (ACC-vaterite-calcite) depicted in Figure 4A,B. As it can be seen, spherulitic 
growth of vaterite crystals via ACC dissolution is replaced by an Ostwald ripening process of crystal 
growth. The further ripening of the vaterite is easily determined by a dissolution-precipitation 
process, which leads to the final calcite [92]. CaCO3 polymorph transformation is governed by 
temperature (Figure 4C) which can be used to prepare particles of a certain phase composition [93]. 
Calcite and aragonite polymorphs have faceted crystals, whereas vaterite particles are usually 
spherical or irregular as shown in Figure 4D. Among the polymorph modifications of calcium 
carbonate, the metastable vaterite is the most practically important because it has large porosity, large 
surface area, and can be dissolved rapidly under relatively mild conditions. Recently, vaterite particles 
were considered to be an excellent drug delivery carriers as well as good bioactive material due to its 
low thermodynamic stability and high solubility [94]. Porous vaterite nano/microparticles offer a large 
surface area for adsorption of compounds of interest and a possibility of their controlled release. 
3.1. Synthesis and Loading of Drugs 
The existing synthesis methods for obtaining CaCO3 nano/microparticles can be divided into 
two categories: chemical [94–97] and microbiological [98–101]. The latter approach is a bacteria-
mediated synthesis, which employs products of microbial metabolism containing carbonate ions 
which react with the calcium ions present in the environment to form CaCO3 [97]. Chemical methods 
are generally based on the emulsion technique [102,103] and the precipitation reaction [104]. The 
conventional approach for the industrial production of CaCO3 is precipitation by carbon dioxide 
bubbling through a calcium containing solution (gas diffusion method) [104,105]. Moreover, chemical 
methods include the controlled double-jet precipitation technique [106–108] and solvothermal 
growth [109]. 
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Figure 4. (A) Schematic illustration of CaCO3 crystallization process; (B) Schematic representation of 
ACC-vaterite-calcite crystallization pathway for the full crystallization reaction in the pure ACC 
system (the green triangles and full black squares represent the ACC and vaterite from this study, 
and the open squares and red triangles represent the vaterite and calcite). Reproduced with 
permission from [92]. American Chemical Society, 2012; (C) initial polymorphic composition of 
CaCO3 in dependence of the temperature. Reproduced with permission from [94]. Elsevier, 2014; (D) 
the typical shapes of calcium carbonate (CaCO3) particles. (A: Average Diameter; B: Crystalline Phase; 
C: Crystalline System). Reproduced with permission from [97]. MedCrave, 2017. 
The most easiest and most cost-efficient way to synthesize the CaCO3 nano/microparticles is 
spontaneous precipitation by mixing supersaturated solutions of calcium (CaCl2 and Ca(NO3)2) and 
carbonate salts (Na2CO3, NaHCO3 and (NH4)2CO3) [102,110,111]. In recent years, many efforts have 
been made to elaborate an in-depth understanding the growth mechanism of CaCO3 and to reveal 
experimental conditions promoting the vaterite particles crystallization. Some of the most impressive 
results in this field are discussed by Costa et al. and Trushina et al. [94,97]. Concentration of the 
applied sources of Ca2+ and CO32−, their type, pH, temperature, mixing speed and the intensity of 
agitation of the reaction mixture is found to determine the resultant CaCO3 polymorph, particle size, 
morphology and stability of the precipitates [94,96,112,113]. Basically, by changing parameters 
determining the number of nucleation sites and the crystal nucleation rate the CaCO3 properties can 
be adjusted. For instance, supersaturation is considered to affect the transformation of CaCO3 
polymorphs during synthesis significantly [114]. Lower nucleation rate delays the formation of more 
stable polymorphs of aragonite and calcite promoting the vaterite precipitation. pH value of the 
exploited solution defines its ionic strength. A higher pH leads to a higher concentration of carbonate 
ions and a higher supersaturation. It was shown that increase of the pH value to 7–11 leads to the 
precipitation of calcium carbonate in the vaterite modification [115]. Moreover, addition of various 
inorganic [101,114,116] and organic substances [6,98,103,111,117,118] containing carboxylic, 
hydroxyl, carboxylate, phosphonate, sulfonate and amino groups induces vaterite particle formation. 
By changing the concentration of additive, molecular weight and the amount of functional groups 
the growth rate, crystal habit and stability, particle size and surface morphology can be controlled 
(Figure 5). Meanwhile, the size and porosity of the CaCO3 crystals can be adjusted without any 
additives simply by changing concentrations of the applied salts, stirring conditions and temperature 
(Figure 5). 
Parakhonskiy et al. studied the influence of CaCO3 particle parameters such as the aspect ratio 
of the particles and their sizes on cell uptake. The authors demonstrated that by controlling physico-
chemical parameters of the synthesis such as pH of solutions, the ratio of salt concentrations, and the 
duration of the reaction the size and shape of the CaCO3 particles can be changed [96]. By adjusting 
the stirring time, the dimension of the particles can be varied at the micrometer range. The geometry 
of the CaCO3 particles (spherical, ellipsoidal and cubical) can be controlled by changing the 
composition of the applied solvent and salt concentration ratio. 
Wang et al. investigated hybrid CaCO3 spheres precipitated from the aqueous solution 
containing carboxymethyl chitosan [119]. Through adjusting the concentrations of Na2CO3 and CaCl2 
solutions the micro- and nanospheres can be obtained. The role of bovine serum albumin (BSA) and 
lysozyme (Lys) in the formation of vaterite is reported in the Ref. [111,120,121]. Thus, synthesis 
conditions can seriously affect the size (from 20 nm to 10 µm with an average pore size of 20–60 nm) 
and shape of the obtained vaterite particles; what in its turn determines their final application, drug-
loading capacity and cell uptake. However, submicrometric particles are considered to be more 
favorable for biomedical applications, since these particles can be more effectively internalized by 
most of cells than their micrometric counterparts. The higher porosity and surface area make vaterite 
nano/microparticles beneficial for the adsorption of a large variety of drugs and biomolecules. 
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Figure 5. (A) Schematic presentation of the three types of synthesis with varied parameters as stirring 
time, the presence/absence of ethylene glycol, the salt ratio S, and the pH of the solutions and scanning 
electron microscopy (SEM) images for the obtained vaterite particles with size diameters of 3.15, 0.65, 
and 1.35 µm vaterite. Reproduced with permission from [122]. Frontiers Media S.A., 2018; (B) SEM 
images of the CaCO3 particles synthesized with varying stirring time and presence/absence of 
ethylene glycol and at pH values of 5, 7, 9 and plots depicted the dependence of particle size from the 
stirring time. Reproduced with permission from [96]. Springer, 2015; (C) SEM images of cross-section 
of CaCO3 microparticle. Reproduced with permission [113]. Royal Society of Chemistry, 2004; (D) 
SEM images of CaCO3 particle grown at different temperature. The pore sizes were found to be 19 ± 
5, 28 ± 9, and 44 ± 13 nm for crystals prepared at 7.5, 22, and 45 °C, respectively. Reproduced with 
permission from [109]. American Chemical Society, 2016; (E) CaCO3 particle size distribution as a 
function of preparation conditions (salt concentration (c), speed (v) and time (t) of salt stirring). 
Parameter variations are on the top of the curves. Orange—salt concentration varied (v = 650 rpm, t = 
30 s); violet—stirring speed is varied (c = 0.33 M, t = 30 s); green—stirring time is varied (c = 0.33 M, v 
= 650 rpm). Reproduced with permission from [123]. Wiley Publishing groups, 2012. 
3.2. Drug Loading 
There are three approaches to load drug molecules into CaCO3 carriers. Active compounds can 
be co-precipitated during synthesis of the CaCO3 [124,125]. Practically, it is applicable for water 
soluble molecules. Impregnation of the prepared particles in a drug solution under constant stirring 
or shaking is another approach [111]. In this case, filling of the pores of synthesized cores can be 
achieved by either physical adsorption of drug molecules or by infiltration. In the latter approach 
organic solvents can be used which allow loading poorly water-soluble drugs. However, it is 
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challenging to develop an impregnation method with high payload, due to the strong solute-solvent 
interactions reduce drug adsorption to the CaCO3. Therefore, sufficient amount of drugs needs to be 
dissolved in a solvent to obtain sufficient drug loads. As an alternative to the impregnation approach 
the solvent evaporation method performed under reduced pressure can be used [126]. This method 
is applicable for the loading of water soluble and poorly water-soluble drugs. In this case, capillary 
forces play a role in driving filling of the pores. 
For the loading of small drug molecules into the CaCO3 charged macromolecules can be 
entrapped in CaCO3 by co-precipitation and then provide additional attractive forces for positively 
charged drugs. There are numerous publications on polymer doping of CaCO3 and spontaneous drug 
loading to the polymer-doped carriers [122,127,128]. 
One of the most promising methods for the drug loading and delivery is fabrication of layer-by-
layer assembled microcapsules composed of oppositely charged polyelectrolytes deposited on 
CaCO3 core [113,129]. This approach is suitable for varous compounds encapsulation, in particular, 
poorly soluble drugs. 
The adsorption of macromolecules inside porous calcium carbonate particles is considered to be 
governed by electrostatic interactions on the CaCO3 surface and protein-protein interactions. 
Moreover, macromolecule adsorption onto solid-liquid interfaces can be determined by several other 
processes such as steric interactions due to the polymeric components at the core surface that extend 
into the surrounding aqueous phase. Changes in the state of hydration and rearrangements in the 
macromolecular structure may take place at regulation of molecules adsorption. Loading of 
macromolecules in porous CaCO3 particles is affected by their molecular weight due to the diffusion-
limited permeation into the particles and by the affinity to the carbonate surface. By adjusting pH of 
the solutions the electrostatic interaction can be altered and, thus, adsorption-desorption process can 
be changed allowing controlling the amount of deposited macromolecules [130,131]. The layer-by-
layer assembled microcapsules possess multiple functionalities such as multicomponent delivery and 
effective multienzyme catalysis [132]. 
Thus, drug-loaded CaCO3 particles are particularly suited for controlled release and delivery of 
a variety of biomolecules. These systems are expected to enhance the bioavailability of poorly 
absorbed drugs, entailing a lowering of the therapeutic dose. Some biological aspects of drug release 
are discussed further. 
3.3. Drug Release 
Since the vaterite particles are the least stable polymorph form of calcium carbonate, they tend 
to transform into calcite in aqueous environment following by the dissolution and crystallization 
[132]. The dissolution-precipitation process of the CaCO3 particles has been shown to allow 
controlling the drug release time. Parakhonskiy et al. have carried out experiments with porous 
vaterite particles of 400 nm in size loaded with rhodamine 6G and tetramethylrhodamine (TRITC)-
dextran [133]. The low molecular weight rhodamine was releasing slowly during the first four days 
of the experiment in water and then the release rate increased dramatically induced by vaterite 
recrystallization. The high molecular weight cargo TRITC-dextran possessed a slow release rate, no 
recrystallization was observed during the first week of incubation. Thus, the polymer entrapped in 
CaCO3 acts as an inhibitor of the phase-transition. Similar effect has been shown by Lauth at el. The 
authors evaluated that the adsorption of bovine serum albumin (BSA) on the surface of CaCO3 
crystals. Results indicated that BSA can slow down the rate of phase transformation of sub-
micrometer vaterite particles [134]. Several examples can be found in the literature where different 
substances are used to regulate the crystallization of CaCO3 particles, such as starch [135], oleic acid 
[136], chitosan [137] and variety of proteins [138–140]. The release of the encapsulated drugs from 
CaCO3 porous structure has been shown to be sensitive to the environmental pH. The 
recrystallization of vaterite particles occurs more readily in acidic media pH < 5, but at neutral pH 
vaterite crystals are less soluble [133,141]. Release in this case is characterized by an initial burst 
release of the drug from CaCO3 particles followed by nearly constant release. Therefore, this makes 
vaterite particles beneficial for their use as pH responsive drug delivery systems, especially for the 
Pharmaceutics 2018, 10, 167 16 of 36 
 
pH triggered release of the anticancer drugs in acidic environment of tumour and inside 
endo/lysosomal compartments of cells [115,142–144]. The release rate can be controlled, depending 
on the size of the particles and their pores [134]. Generally, it decreases with the decrease of the pore 
size. Capping the CaCO3 cores with multilayers allows tuning the release profile of the encapsulated 
drug as has also been shown in the literature [135,136]. Figure 6 depicts the typical release mechanism 
of anticancer drug loaded in CaCO3 particles at various pH. Schematic representation demonstrates 
a locking/unlocking mechanism of the burst drug release within cancer cells by using ACC carriers 
covered with an oleic acid (OA) shell and a polyethylene glycol (PEG) corona [136]. Figure 6E 
illustrates the above-mentioned statements and shows cumulative release profiles at different 
temperatures and pH values (7.4, 6.5, and 5.5) mimicking the microenvironment of healthy tissue, 
tumor tissue, and cellular lysosomes, respectively (Figure 6A–C) [135]. 
 
Figure 6. Schematic description of the pH-responsive drug release of ACC-DOX@silica nanoparticles. 
Reproduced with permission from [145]. Wiley Publishing Groups, 2012. Cumulative releases of 
doxorubicin (DOX) from ACC-DOX@silica suspensions in various aqueous buffers at (A) pH 7.4; (B) 
pH 6.5 and (C) pH 5.5 with different temperatures of 25, 37 and 50 °C. Representative TEM images of 
the suspensions under 37 °C at (D) pH 7.4; (E) pH 6.5 and (F) pH 5.5. Reproduced with permission 
from [145]. Wiley Publishing Groups, 2012. The scale bars are 500 nm. (G) Schematic illustration of 
assembly process and disassemble mechanism of PEG/OA-ACC-DOX within cancer cells. 
Reproduced with permission from [136]. Royal Society of Chemistry, 2017. 
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Adsorption of macromolecules allows preserving particle in vaterite polymorph, slowing down 
the process of recrystallization and decrease drug release rate [146]. Borodina et al. investigated the 
effect of the different coatings such as hyaluronic acid, poly L-lysine and surfactant (Tween 80) on 
loperamide release out of the CaCO3 carrier. The obtained results showed 10% of the release extension 
for microparticles modified with hyaluronic acid [147]. 
3.4. Delivery of Various Compounds In Vitro and In Vivo 
The sustained release of drugs from the CaCO3 particles was confirmed both in vitro and in vivo 
experiments (Table 2). It possesses unique advantages due to their biocompatibility and the ability 
for loading different therapeutic agents. Studies show that CaCO3 nano/microparticles can be used 
as vectors to deliver various biological substances such as drugs [143,148], proteins [111,143,147,149], 
peptides [150,151] and genes [132,152]. Due to high biocompatibility, biodegradability, and pH 
sensitive features, vaterite and ACC show promising potential for the development of the drug 
delivery system for cancer treatment [143,148]. As it has been already mentioned, tumor tissues (pH 
6.5–6.8), cell endosomes (pH 5.5–6.5), lysosomes (pH 4.5–5.5) and blood stream and normal tissues 
(pH 7.4) have different pH conditions [153]. Som et al. conducted in vivo experiments and showed 
that monodispersed CaCO3 nanoparticle can be used to intentionally modulate local pH and inhibit 
tumor growth. The authors evaluated that CaCO3 particle size affects alkalinization efficiency of the 
acidic pH of tumors. Dissolution of submicron particles of CaCO3 in vivo was shown to increase pH 
asymptotically to 7.4 [106]. 
Doxorubicin as anti-cancer drug is often employed to investigate the CaCO3 carrier system. Zhao 
et al. studied co-delivery of doxorubicin and Au–DNA nanoparticles by using CaCO3 carrier for drug 
and gene therapy [135,154]. It has been shown that the devolved vehicle exhibits high efficiency in 
nuclear invasion. The drug is observed to be widely distributed in the tumor tissue. Dong et al. 
applied the CaCO3 nanoparticles to deliver photosensitizer Hypocrellin B as a model hydrophobic 
anticancer drug. High toxicity of the particles has been detected in vitro by using breast cancer cell 
line (MCF-7) under light irradiation. Another water-insoluble anticancer drug, camptothecin, 
encapsulated in CaCO3 microspheres has been investigated by Qiu et al. [111]. 
On the basis of CaCO3 carriers multi-drug delivery systems consisted of doxorubicin and 
additional hydrophobic drug (paclitaxel or tariquidar) were developed by Wu et al. [137,155]. It has 
been shown that the dual drug loaded nanoparticles enhanced cell inhibitory effect, especially for 
drug resistant cancer cells. As it has been shown in the previous section, besides vaterite particles, 
ACC carrier can be applied for a burst release of its payload within cancer cells (Figure 6G). The pH-
responsiveness of the ACC-DOX@silica nanoparticles after uptake by HeLa cells determines the 
sustained killing effects in the intracellular physiological environment as reported by Zhao et al. 
[145]. 
The antibacterial activity and pH-dependent drug release have been observed for CaCO3 
microstructures containing tetracycline-entrapped polypeptides [150]. It has been shown that the 
encapsulated drug or the dye-conjugated peptide emits fluorescence suitable for optical imaging and 
detection, thereby making it a multitasking material. 
CaCO3-based composite nanocarriers have potential for the peptide and protein pulmonary 
aerosol delivery and oral administration of insulin [156]. Liu et al. demonstrated that an improved 
hypoglycemic effect in vivo can be obtained compared with subcutaneous injection of insulin on a 
rat model [156]. 
Based on the given literature review, it can be concluded that CaCO3 porous carriers have a very 
prospective potential for site-specific drug delivery. However, calcium carbonate carriers also 
possess certain drawbacks, which should be taken into account. The synthesis procedure of calcium 
carbonate particles is in the most cases very sensitive and, thus, not always 100% reproducible. Slight 
variations of external temperature, speed of reaction mixing, purity of the precursors for the reaction 
can result in the size and shape changes of the calcium carbonate particles. 
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Active Drug In Vitro/In Vivo Results Ref. 




Resulted carriers modulated local pH and 
repeated daily administration of nano-
CaCO3 inhibit tumor growth up to 2-fold 
in comparison with control. Efficient 
alkalization of the acidic pH of tumors 
depended on the particle size. 
[106] 
CaCl2 + NaHCO3  
1:5 DI H2O:polyethylene 
glycol 
Mix for 5 min 
20 nm 
CaCl2 + NaHCO3  
1:5 DI H2O:ethylene glycol 
Mix for 30 min 
300 nm 
NH4HCO3 vapor diffusion 
through CaCl2 in EtOH 
oleic acid stabilizer and 
polyethylene glycol corona 
600 nm Doxorubicin 
ACC particles with an oleic acid shell and 
a polyethylene glycol (PEG) corona 
showed retarded drug release profile with 
merely 14% of the drug being released 
after 24 h, decreased pH value up to 5.5 
did not drastically increase the drug 
release, revealing that the drug locking 
effect was well realized. 
[136] 
CaCl2 + NaHCO3  
water:gelatin:ethylene glycol 




The cellular internalization of hybrid 
nanoparticles modified by cross-linked 
hyaluronic acid by MCF-7 cells 
overexpressing cell-surface glycoprotein 
(CD44 receptor) has been enhanced from 
2.2% to 85%, endowing the nanoparticles 
with targeting functionality. 
[153] 
CaCl2 + NaHCO3  
starch solution 




Qualitative CLSM observations showed 
efficient intracellular delivery of 
doxorubicin by the CaCO3 carriers and 









The IC50 (half maximal inhibitory 
concentration) values for various cell lines 
indicated relatively greater cell inhibition 
(from 1.8 to 8 fold) in the case of all the 
three cancer cell lines (A549, epithelial 
human breast cancer cell line (MDA-MB-
231) and HeLa) in comparison to the 
normal cells. 
[150] 
CaCl2 + NaHCO3  
ethylene glycol (EG), gelatin 
Mix for 2 h 
230 nm Doxorubicin 
Vaterite nanoparticles embedded with 
folic acid containing doxorubicin 
exhibited 2-fold higher cytotoxicity to 
MCF-7 cells compared with that of drug-
loaded vaterite particle and free drug at 
concentrations of 0.02 and 0.04 mg/mL. 
[154] 
Spray Drying 








The bioavailability of salmon calcitonin 
after aerosol delivery as peptide-loaded 
composite microparticles to rats was 4-
times higher than that of salmon 
calcitonin solution. 
[151] 
Starch solution and starch-
octanoic acid were set as 
templates to prepare CaCO3 
nanoparticles from CaCl2 + 
NaHCO3  




The IC50 of drug-loaded nanoparticles 
synthesized using 0.0625% starch-octanoic 
was almost 24-fold higher than that of 
DOX·HCl indicating higher A549 cellular 
uptake and faster drug release at the 
acidic pH. 
[148] 
CaCl2 + NaHCO3  




An effective hypoglycemic effect was 
obtained in vivo compared with 
subcutaneous injection of insulin. After 
oral administration of insulin-loaded 
CaCO3 the blood glucose level is 
decreased 2-times slower for 3 h than that 
of with using insulin solution. 
[156] 
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Qualitative CLSM observations showed 
that the dual drug loaded nanoparticles 
exhibited significantly enhanced cell 
uptake and nuclear localization as 
compared with the single drug loaded 
nanoparticles. 
[155] 







Enhanced multidrug-resistant breast 
cancer (MCF-7) cells uptake and nuclear 
localization were observed qualitatively 
for the drug-loaded nanoparticles by 
CLSM. Drugs co-delivery systems 
demonstrated near 2-fold higher cell 
inhibition rates compared with 
doxorubicin delivery systems. 
[137] 
4. Calcium Phosphate Carriers 
Calcium phosphate-based nanostructured materials are widely used in different applications in 
biology and medicine due to its biocompatibility and biodegradability [157,158]. An obvious 
advantage of calcium phosphate is its well-known osteoinductivity, this material is often used as a 
tissue implant and bone substitute [159–161]. Calcium phosphate is also often employed as drug 
delivery carrier of genetic materials [162,163], commercial drugs [164] and other bioactive molecules 
[165]. This material can be porous, what increases loading capacity of carriers and, thus, efficiency of 
delivery. Moreover, it is known that calcium phosphate dissolves at slightly acidic pH [166], what 
enables the possibility of controlled drug delivery into cells. After dissolution of the calcium 
phosphate carriers, ionic non-toxic constituents Ca2+ and PO43− remain, and this prevents particle 
accumulation and induces intracellular drug release [167]. All these features of calcium phosphate 
make this material attractive for the drug delivery applications. 
4.1. Synthesis of Calcium Phosphate 
There are many different methods to produce calcium phosphate particles with different 
morphologies and sizes. For the drug delivery applications, porous calcium phosphate particles are 
of the particular relevance due to increased loading capacity. A traditional synthesis method of 
porous calcium phosphate nanosized materials involves mixing of water soluble salts of calcium and 
phosphate. With this technique, it is possible to control size, shape and crystallinity of particles by 
changing conditions of the precipitation reaction. For example, to obtain porous calcium phosphate 
spherical nanoparticles microwave assisted hydrothermal method is often used. This method 
involves adenosine 5-triphosphate disodium salt (ATP) as the phosphorus source and stabilizer 
(Figure 7A) [168]. As an example, Qi et al. synthesized porous calcium phosphate particles with an 
average diameter 260 nm by mixing calcium chloride dehydrate with ATP and further microwave 
treatment. The resulted nanoparticles showed good stability in aqueous solutions at different pH for 
more than 150 h, what is much longer than previously reported porous calcium phosphate particles 
[169]. Alternatively, porous calcium phosphate nanoparticles with different morphology and 
crystallinity can be prepared by changing the ratio of precursors. Kondori et al. showed that calcium 
phosphate particles can be synthesized by aging a mixture of calcium hydroxide and sodium 
triphosphate in the presence of hydrochloric acid [170]. To obtain differently shaped particles, 
authors varied aging temperatures from 100 to 150 °C, as well as amount of precursors in the reaction. 
Moreover, hollow calcium phosphate nanoparticles can be obtained with the templating method 
(Figure 7C) [171]. Different materials can be employed as templates. For example, Ding et al. used 
soybean lecithin to form calcium phosphate hollow particles. Another materials, which can be used 
as the template to form hollow calcium phosphate particles, are block copolymer micelles (Figure 7D) 
[172]. Bastakoti et al. used an anionic triblock copolymer (poly (styrene-acrylic acid-ethylene glycol) 
to form calcium phosphate hollow particles. This kind of template helps to overcome the problem of 
crystal overgrowth and allow the formation of nanosized hollow particles around 30 nm. Liposomes 
are also used as templates to form hollow calcium phosphate particles [173–175]. Yeo et al. employed 
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1,2-dioleoyl-sn-glycero-3 phosphate sodium salt (DOPA) and 1,2-dipalmitoyl-sn-glycero-3-
phosphate sodium salt (DPPA) as templates due to their negative charged head group, which can 
help the deposition of calcium and phosphate ions around the liposomes. Resulted hollow particles 
were 64 and 104 nm, respectively (Figure 7E). Polymer complexes can be also employed as templates 
to form hollow calcium phosphate particles (Figure 7F) [176]. Zhang et al. prepared hollow calcium 
phosphate microspheres using chitosan-poly acrylic acid (CS-PAA) as the template. The formation 
mechanism of the hollow structure was based on the electrostatic interactions between chitosan (CS) 
and poly acrylic acid (PAA). The authors also showed that the size of CS-PAA spheres could be 
adjusted by changing the ratio and concentration of CS and PAA in the reaction. 
 
Figure 7. (A) SEM image of amorphous calcium phosphate particles synthesized by using CaCl2·2H2O 
as the calcium source and ATP as both the phosphorous source and stabilizer by microwave-assisted 
hydrothermal method at 120 °C for 10 min. Reproduced with permission from [168]. Wiley Publishing 
Groups, 2013; (B) TEM images of calcium phosphate precipitates. Reproduced with permission from 
[177]. Bulletin of the Chemical Society of Japan, 2008; (C) TEM image of hollow calcium phosphate 
particles prepared using soybean lecithin, Na2ATP and CaCl2 by the microware-assisted 
hydrothermal method at 120 °C. Reproduced with permission from [171]. Royal Society of Chemistry, 
2015; (D) TEM image of hollow calcium phosphate nanospheres. Reproduced with permission from 
[172]. Royal Society of Chemistry, 2012; (E) Transmission electron microscopy (TEM) image of calcium 
phosphate nanoshells synthesized with templates of DOPA. Reproduced with permission from [173]. 
Elsevier, 2012; (F) TEM image of calcium phosphate spheres. Reproduced with permission from [176]. 
IOPscience, 2009. 
Given the nature of encapsulated drugs, they can be entrapped into calcium phosphate particles 
or attached onto the particles surface. For the first scenario, drugs are usually caged into the particles 
matrix during their formation. This can be done with conventional co-precipitation reaction, drugs-
calcium phosphate co-precipitates arise spontaneously in supersaturated solutions. Addition of the 
drugs during the synthesis of the particles can affect their physico-chemical properties. However, if 
prolonged intracellular release of drugs is needed, embedding of drugs into the interior of particles 
is more preferable. Alternatively, drugs to deliver can be attached onto the particles surface after 
calcium phosphate particle synthesis. In this case, however, drugs are less protected from the intra- 
and extracellular environment [178]. 
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4.2. Release Efficiency 
Intracellular release of drugs from calcium phosphate particles can be usually controlled. 
Loaded drugs can be released in a prolonged way during the degradation of calcium phosphate 
particles in the acidic environment of the endosomal/lysosomal compartments (Figure 8) [179]. This 
stimuli-responsive behavior of calcium phosphate makes this material attractive for the drug delivery 
applications. Moreover, previous studies hypothesized cytosolic release of cargo delivered with 
calcium phosphate carriers. The dissolution of calcium phosphate particles induces the 
endosomal/lysosomal escape of delivered cargo due to the swelling and further bursting of these 
compartments and, consequently, intracellular release of cargo inside cells [150]. Interestingly, the 
release of cargo from calcium phosphate particles dispersed in slightly acidic pH can be controlled. 
Resent findings showed that cargo release from calcium phosphate particles, synthesized at different 
temperatures, is dependent on resorption of these particles [180]. Matsumoto et al. investigated 
release of proteins from calcium phosphate particles by immersion of particles in solutions at pH 4 
and 7. The amount of released proteins from the particles immersed in the solution at pH 7 was 
significantly smaller than from solution at pH 4. Another way to control release of drugs with pH is 
employing of calcium phosphate as pore blocker material for mesoporous silica particles. Pores of 
this composite material can be loaded with drugs, whereas calcium phosphate coating can hold the 
encapsulated drugs under extracellular conditions. Inside cells calcium phosphate can be dissolved 
initiating intracellular drug release from the pores of mesoporous silica particles [56]. 
For the burst drug release from calcium phosphate particles, an external physical impact can be 
applied. For example, it has been shown that calcium phosphate nanospheres can be destroyed under 
the ultrasound treatment [181]. Cai et al. synthesized nanosized hollow calcium phosphate particles 
by a wet chemical reaction, and cetyltrimethylammonium bromide (CTAB) was used as a modifier. 
Ultrasound treatment induced the deconstruction of these hollow particles resulted in pin-like 
nanocrystallites of calcium phosphate. 
 
Figure 8. Schematic illustration of calcium phosphate particle degradation inside 
endosomal/lysosomal compartment (endosomal/lysosomal compartments are in orange color, 
enzymes/proteins are in green color, spherical calcium phosphate particle is in grey color, delivered 
cargoes are orange rhombs and green triangles). 
4.3. In Vitro and In Vivo Delivery of Various Compounds with Calcium Phosphate Carriers 
Nucleic acids are the main compounds, which can be successfully delivered with calcium 
phosphate particles (Table 3) [182–184]. The first report related to the use of calcium phosphate as 
non-viral vector was made in 1973 by Graham and van der Eb [185]. Nowadays, in vitro transfection 
with calcium phosphate precipitates is a standard laboratory procedure. This method is cost-effective 
and easy-to-use; however, it suffers from some disadvantages, such as low reproducibility and poor 
transfection efficiency [186]. Pedraza et al. showed that transfection efficiency is reduced with 
aggregates of calcium phosphate particles loaded with DNA with sizes much higher than 200 nm. 
Removing the large agglomerates with filtration resulted in size of calcium phosphate particles much 
less than 200 nm and, thus, in an improved transfection of cells. More efforts were made to reduce 
the size of calcium phosphate particles. Calcium phosphate nanoparticles (less than 100 nm) showed 
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improved biocompatibility and transfection efficiency in vitro [187,188]. Ultrasmall sized particles 
(20–50 nm) were synthesized by Cao et al. These particles were employed to deliver DNA into 
mesenchymal stem cells in vitro. Calcium phosphate particles had significantly lower toxicity in 
comparison to commercial transfection reagents, e.g., Lipofectamine 2000 [188]. Elangovan et al. 
successfully synthesized 30–50 nm calcium phosphate nanoparticles loaded with genes. These 
particles were then employed to transfect fibroblasts in vitro. Interestingly, transfection studies 
revealed a higher and longer lasting transfection up to 96 h. Qiu et al. showed that high accumulation 
of calcium phosphate particles loaded with small interfering RNA (siRNA) in tumor led to a 
significant tumor growth inhibition with a specific gene silencing effect in vivo [189]. In vivo 
distribution of these particles in an A549-xenografted mouse showed significant accumulation in the 
liver after first 12 h with further excretion by renal metabolism after 48 h (Figure 9). Another study 
showed anti-inflammatory effect of calcium phosphate particles loaded with siRNA in vivo. siRNA 
was directed against tumornekrosefaktor (TNF-α), keratinocide-derived cytokine (KC) or interferon 
gammainduced protein (IP-10) to mice suffering from induced colonic inflammation [190]. Multiple 
therapeutic agents can be delivered with the carriers based on calcium phosphate. Zhou et al. 
demonstrated successful co-delivery of inhibitors for microRNA221 and microRNA-222 (miRi-
221/222) and paclitaxel (pac) [191]. As the result, compounds were delivered into MDA-MB-231 cells 
inhibiting the proliferative mechanism of miR-221/222, cyclin-dependent kinase inhibitor (p27Kip1) 
and tissue inhibitor of metalloproteinase 3 (TIMP3). 
 
Figure 9. In vivo distribution of calcium phosphate particles loaded with siRNA observed by the in 
vivo imaging system. The nude mice bearing the A549 tumor was given intravenous injection via tail 
vein. Reproduced with permission from [189]. Royal Society of Chemistry, 2016. 
To increase the local drug concentrations in the desired areas and minimize the risks of the 
systemic toxicity, capsulate drug delivery systems based on calcium phosphate have been developed 
[192]. Xu et al. successfully encapsulated hydrophobic drug indomethacin into the cavity of calcium 
phosphate particles. Another toxic drugs, like cisplatin [193], were encapsulated into the cavity of the 
liposomes and at the same time liposomes were employed as templates for biocompatible calcium 
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phosphate. The architecture of hollow calcium phosphate spheres benefits due to improved loading 
capacity and pH-sensitivity. Moreover, it has been reported that calcium phosphate coating reduces 
drug release rate in comparison to the uncoated liposomes enabling prolonged drug release [192]. 
Hydrophobic drugs can be also loaded within the calcium phosphate shell with the same templating 
method [173,192]. 
Verma et al. reported for the first time the use of Vitamin B12 conjugated with calcium phosphate 
particles loaded with insulin for the enhance the absorption of the particles by multiple pathways 
apart from the gastric intrinsic factor (IF) receptor mediated endocytosis. These delivery systems can 
be effectively applied for the oral administration. Photodynamic therapy of tumor in vivo was also 
realized with calcium phosphate particles loaded with the photosensitizer Temoporfin. These 
particles were additionally functionalized with peptides for targeted delivery into endothelial cells. 
After 2 days of particle treatment of mice, apoptosis in the tumor was detected [194]. Moreover, tumor 
vascularization was destroyed what makes calcium phosphate particles very promising drug 
delivery system. 
Despite this, calcium phosphate have some limitations as drug delivery platform. First of all, as 
it has been mentioned above, calcium phosphate carriers are mostly used to deliver nucleic acids into 
cells. However, transfection efficiency of these carriers is still poor in comparison with commercial 
reagents (e.g., Lipofectamine) or viral carriers [188]. Moreover, encapsulated materials are limited to 
solubility in water or organic solvent [195]. Nevertheless, calcium phosphate nanoparticles are 
commonly accepted to be a nontoxic, biocompatible, and resorbable material and, thus, suits as 
nanocarrier for the drug delivery applications [196]. 




Active Drug In Vitro/In Vivo Results Ref. 
Water-in-oil micro-emulsion 
method 
CaCl2 (in Cyclohexane/Igepal) + 
Na2HPO4 (pH = 9.0) in oil 
Mix for 20 min 
40 nm siRNA 
A 40-fold improved silence activity 
compared to the previous analogous 
formulations. Reported nanoparticle 
vehicles effectively delivered siRNA to a 
solid tumor in a xenograft model in vitro 
and in vivo. 
[182] 
CaCl2 + Na3Cit + Na2HPO4 at 
pH 8.5 





Calcium phosphate nanoparticles 
efficiently internalized into 
cardiomyocytes. Dose-response graphs are 
given. The nanoparticles did not show 
promoting toxicity or interfering with any 
functional properties. Nanoparticles 
successfully encapsulated synthetic 
miRNAs, which were efficiently delivered 
into cardiac cells in vitro and in vivo. 
[183] 
CaCl2 (in Cyclohexane/Igepal) + 




Resulted calcium phosphate carriers 
showed multifunctional features. 
PEGylation of these carriers enabled 
delivery to hepatocytes in vivo. Co-
delivery of cationic peptides CR8C 
supported extensive nuclear translocation 
of DNA in post-mitotic cells. Monocyclic 
CR8C significantly enhanced in vivo gene 
expression over 10-fold more than linear 
CR8C. Carriers had improved stability and 
protecte DNA from degradation, though 
100-fold lower in gene expression was 
detected, the developed system presents a 
greatly decreased invasiveness in its 
application. 
[184] 
CaCl2 in bis (2-ethylhexyl) 
sulphosuccinate (in hexane) + 





Resulted carriers showed the transfection 
efficiency of 3% higher than that from the 
commercial transfecting reagent Polyfect. 
[197] 
Pharmaceutics 2018, 10, 167 24 of 36 
 
Mix overnight at 4 °C 
Ca(NO3)2 + (NH4)3PO4 





Effective transfection with calcium 
phosphate particles in different cell types 
was demonstrated. 
[186] 
CaCl2 (in Cyclohexane/Igepal) + 
Na2HPO4 (in Tris-
HCl/Cyclohexane/Igepal) 




Resulted DNA carriers showed 5.7% lower 
cytotoxicity than commercial reagent 
Lipofectamine 2000. It has been 
demonstrated that calcium phosphate 
nanoparticles can be developed into an 
effective alternative as a non-viral gene 
delivery system. 
[188] 







DNA and growth 
factors 
Synthesized calcium phosphate particles 
showed higher levels of biocompatibility 
(between 84% and 95% of mouse embryo 
(NIH-3T3) fibroblasts viability) and 
transfection efficiency into fibroblasts in 
vitro. Enzyme-linked Immunosorbent 
Assay (ELISA) test showed 3-fold higher 
platelet-derived (PDGF-B) growth factor 
expression in NIH-3T3 fibroblast cell line 
upon administration of nanocarriers than 
that of other applied substances. 
[187] 
CaCl2 + Alendronate-
hyaluronic acid conjugate(in 
HEPES) 
170 nm siRNA 
Resulted calcium phosphate carriers 
showed effectively delivered siRNA in the 
A549 cells and contributed to the gene 
silencing (with the efficiency of about 40%) 
in vivo and in vitro. 
[189] 
C6H12CaO6 + (NH4)2HPO4 150 nm siRNA 
Particles exhibited rapid cellular uptake, 
almost no toxicity, and reduced gene 
expression of approximately 50% 
compared to the controls. A specific 
knockdown of target genes at the site of 
inflammation was achieved. 
[190] 








Carriers loaded with multiple drugs 
simultaneously delivered paclitaxel and 
miRNA-221/222 inhibitors to their 
intracellular targets, leading to inhibit 
proliferative mechanisms of mRNA-
221/222 with further enhancing the 
therapeutic efficacy of paclitaxel. It was 
demonstrated that the co-delivery 
nanocarrier system had 80% efficiency of 
tumor cell suppression when compared to 
free paclitaxel or delivering nanocarrier 
with a single drug (i.e., miRi only or 
paclitaxel only). 
[191] 
Ca(NO3)2 + K2HPO4 
Stir for 1 h 
129 nm Cisplatin 
Synthesized calcium phosphate 
nanoparticles were non-toxic. Drug-loaded 
nanoparticles showed comparable 
cytotoxicity to free drug in an in vitro cell 
proliferation assay using the cisplatin-
resistant human ovarian carcinoma 
(A2780cis) cell line. Negatively charged 
drug nanoconjugates are unable to 
overcome drug resistance and had the 4-
fold increase in IC50 value as compared to 
the free drug. 
[193] 
C6H10CaO6 + (NH4)2HPO4 









Efficient drug delivery resulted in 2 times 
decrease in tumor vascularization in 1 
week of treatment in vivo. Synthesized 
carriers combined diagnostic imaging, 
tumor targeting and drug delivery 
properties. 
[194] 
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5. Concluding Remarks and Future Research Directions 
As it has been reported above, the porous inorganic materials such as mesoporous silicas, 
calcium phosphates and calcium carbonates were widely applied as carriers in the drug delivery 
applications. These systems possess multiple features such as high loading of bioactive substances, 
in vivo navigation and visualization, remote release of cargo by internal and external stimuli. The 
morphological and surface properties of silicas, calcium carbonates and calcium phosphates allows 
to perform the organic functionalization in order to develop novel efficient hybrid carriers with 
enhanced multimodal properties. Moreover, there are a lot of possibilities for the in situ co-
encapsulation of various bioactive compounds (drug, gene, protein, fluorescent molecule, etc.). 
However, these materials can also possess certain drawbacks, which are associated with their 
safety and stability. Although these materials are considered to be non-toxic, it is always important 
to control the concentration of employed particles in order to avoid adverse effects. Moreover, when 
working with biological fluids (cell culture medium, blood plasma etc.) more factors concerning 
stability of particles should be considered. For instance, organic compounds in biological fluids tend 
to bind to surface of drug carriers, forming so-called corona around the particles. This corona can 
significantly change physico-chemical properties of particles, resulting in particles aggregation. 
Therefore, they should be characterized not only in aqueous solutions, but also in biological fluids. 
In general, it can be concluded that the silica-based carriers are mostly used for the delivery of 
antitumor drugs and fluorescent dyes while calcium phosphate carriers are more appropriate for the 
delivery of genetic materials (e.g., DNA, microRNA, siRNA) and osteogenic factors (e.g., 
dexamethasone) for the bone tissue engineering. The calcium carbonate particles are mostly applied 
for the delivery of anticancer drugs (doxorubicin, vincristine, etc.), osteogenic factors and protein 
encapsulation. 
The sol-gel chemistry is used for the fabrication of porous silica-based carriers. As for the silica-
based carriers, combination of sol-gel chemistry, organic functionalization, and surface decoration 
with inorganic nanoparticles is a key principle for creation of nanostructured hybrid silica carriers 
with fundamentally new features. The introduction of organic components into the silica frameworks 
(e.g., the incorporation of disulfide bonds) leads to an interesting responsive degradation behavior 
and drug release. However, it is still difficult to prepare the organic-functionalized silica carriers with 
well-defined structures. Therefore, the fabrication of porous organic-inorganic silica carriers with 
high stability is highly desirable. 
The preparation of calcium carbonate carriers with loaded drugs is mainly based on emulsion 
techniques and chemical precipitation. Usually pH-sensitive properties of calcium carbonate are used 
for release of anticancer drugs. Since the pH of tumor tissues bellow 6.5, it is still important to develop 
targeted drug carriers based on calcium carbonate nanoparticles. To increase the targeted delivery, 
the nanostructures of calcium carbonate should be functionalized with targeting agents. Moreover, 
there are some problems, such as incomplete in vivo release of drugs or/and incomplete degradation, 
that should be considered to improve the drug delivery properties of calcium carbonate. 
The use of calcium phosphate carriers for the drug delivery application requires specific 
functionalities, which are difficult to develop. However, recent progress in nanofabrication 
technologies opens possibilities to fabricate nanostructures of calcium phosphate with diverse 
morphology, size and composition. At present, we may highlight that calcium phosphate is mostly 
used for co-precipitation with DNA to perform gene delivery. The main disadvantages of the calcium 
phosphate gene transfer system are not always sufficient transfection efficiency and poor 
reproducibility compared with other non-viral carriers (e.g., Lipofectamine 2000). Although a lot of 
new methods based on the calcium-phosphate-DNA precipitation have been developed to enhance 
transfection efficiency, it is vital to improve the transfection efficiency using new synthetic 
approaches, for example, combining calcium phosphate carriers with other materials. The 
combination of porous inorganic carriers with organic/inorganic nanomaterials creates a synergetic 
effect for drug delivery applications and diagnostics. 
In the near future, scientists should pay more attention to in vivo biosafety and degradation of 
drug carriers. Even though a great amount of different porous carriers was developed, most of them 
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not introduced into preclinical studies. This is mostly because used for the functionalization of porous 
carriers compounds and carriers itself are not always approved by the medical committee. Moreover, 
more experimental data are needed to study the mechanism of the in vivo degradation of carriers 
and their removal from the body. The clear understanding of how the composition/structure of 
porous drug carriers affects the in vivo safety and degradation could pave the way for the improved 
treatment of diseases with higher biosafety. 
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